Wutah pendapatan taun lumaku: I-Mab (IMAB)

Logo perusahaan publik I-Mab Biopharma Co., Ltd. (IMAB)

I-Mab is undergoing a large-scale resource reallocation following a structural split, which maintains high risk volatility. The business model is based on selling antibody rights to Western corporations after primary testing in China, thereby minimizing capital expenditures. Success depends on the effectiveness of the immunotherapy portfolio and the regulatory environment. This chart of the rolling 12-month YoY revenue growth demonstrates real sales dynamics, where the indicator reached the level of 0.00.

I-Mab Biopharma (IMAB): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 20.02.2024

I-Mab Biopharma - rincian analitis lan metrik utama (IMAB)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:i-mabbiopharma.com
Produk merek i-mabbiopharma.com

To minimize risks, investors should track demand dynamics for I-Mab (IMAB) drugs, utilizing relative revenue growth over the last four quarters compared to the previous year as a filter for market cycles. Portfolio diversification of antibodies and global partnerships ensure stability, while an upward trend in this indicator confirms the actual expansion of the company's commercial presence, preventing overpayment for fading business development momentum.

Karo sapa I-Mab saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku Fennec Pharmaceuticals FENC|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur